Although leucovorin boosts 5-FU’s response rate from 20% to roughly 30% in colorectal cancers, single-agent 5-FU more effectively suppresses thymidylate synthase (TS) in human intestinal tissue [41], suggesting resistance mechanisms. The gene discussed is TYMS; the disease is colorectal cancer.